-
<![CDATA[Investigational Bictegravir–Lenacapavir Single-Tablet Regimen Noninferior to Standard Therapy in Phase 3 ARTISTRY-2 Trial]]>
16 Dec 2025 23:47 GMT
… regimen containing emtricitabine and tenofovir alafenamide, according to a … the US Food and Drug Administration (FDA) snapshot algorithm.1
… and Research at the Medical University of South Carolina, … treatment meets primary endpoint in phase 3 ARTISTRY-2 trial. …
-
Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in People with HIV: A Real-World Data from the Spanish BICSTaR Cohort
16 Dec 2025 20:19 GMT
… side effects, dosing, drug interactions, resistance test … Ethical Guidelines for Medical and Health Research … ;emtricitabine/tenofovir alafenamide in treatment experience patients. … HIV clinical trials evaluating antiretroviral treatment: a systematic …
-
<![CDATA[Gilead’s ARTISTRY-2 Trial Shows Bictegravir Lenacapavir Combo Matches Biktarvy in Virologically Suppressed Adults With HIV]]>
16 Dec 2025 03:13 GMT
… emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, … care and research, Medical University of South Carolina … complex antiretroviral treatment regimens may experience pill burden, adherence … with HIV. Applied Clinical Trials. November 13, 2025. …
-
Gilead’s HIV ART combo deemed non-inferior in second Phase III trial
15 Dec 2025 20:01 GMT
… trial (NCT06333808), patients were switched from Biktarvy (bictegravir 50mg, emtricitabine 200mg, tenofovir … treatment gained approval from the US Food and Drug Administration (FDA … discovering their medication or adherence … .
Clinical Trials Arena Excellence …
-
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
15 Dec 2025 17:00 GMT
… emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, … results from the ARTISTRY trials with regulatory authorities … USA Award for Best Pharmaceutical Product. About Gilead … long-acting injectable HIV treatment medication administered twice-yearly. Our …
-
Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal
15 Dec 2025 17:38 GMT
… Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide, B/F… 3 results from the ARTISTRY trials with regulatory authorities and submit … Two-Drug Regime Matches Gilead’s Three-Drug Tablet For HIV Treatment
Trial Data …
-
HIV and HCV Screening, and Pre-Exposure Prophylaxis Among Managed Care Beneficiaries with Substance Use Disorders: A Cross-Sectional Study from a Single State
16 Dec 2025 20:19 GMT
… and tenofovir alafenamide), truvada (emtricitabine and tenofovir … treatment programs: study protocol for a hybrid design randomized controlled trial. Trials … drugalcdep.2021.108878
42. Madden EF. Intervention stigma: how medication-assisted treatment …
-
<![CDATA[Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Meets Primary Endpoint in Phase 3 Study]]>
15 Dec 2025 19:39 GMT
… ;emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B … Patient Care and Research, Medical University of South Carolina, … data from the ARTISTRY trials with regulatory authorities and … HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial. …
-
Otosyphilis and Malignant Syphilis in a Human Immunodeficiency Virus–Infected Patient: A Case of Bilateral Hearing Loss with Complete Recovery Following Ceftriaxone Therapy – Case Report
16 Dec 2025 20:19 GMT
… subsequently with a combination of tenofovir, lamivudine, and dolutegravir. However … noise-induced injury, presbycusis, medication toxicity, and systemic inflammatory conditions … may include delays in treatment, insufficient treatment, irreversible damage, or …
-
Gilead's single-tablet HIV combo of bictegravir, lenacapavir passes another late-stage test on way to filings
16 Dec 2025 18:32 GMT
… HIV medicine Biktarvy when assessing patients' treatment responses, … to Biktarvy, meeting the trial's primary endpoint … the antivirals emtricitabine and tenofovir alafenamide. Lenacapavir is a … trials will allow Gilead to provide a simplified 2-drug …
About
© 1995-2025